Optimization of chimaeric HIV-1 virus-like particle (VLP) production and immunogenicity testing of VLPs in mice [PDF]
, 2008 Includes abstract.Includes bibliographical references (leaves 139-148).The devastating effect the HIV pandemic has had on the human population in the last twenty five years has highlighted the great need to develop a prophylactic HIV vaccine.
Pillay, Sirika
core +1 more source
Multiplex Human Papillomavirus L1L2 virus-like particle antibody binding assay
MethodsX, 2022 A variety of in vitro techniques are available to estimate the level of antibodies present in human serum samples. Such tests are highly specific and are used to determine prior exposure to a pathogen or to estimate the magnitude, breadth and durability ...
Kavita Panwar +7 more
doaj +1 more source
Virus-like particles for vaccination against cancer. [PDF]
, 2020 Active immunotherapy of cancer aims to treat the disease by inducing effective cellular and humoral immune responses. Virus-like particle-based vaccines have evolved dramatically over the last few decades, greatly reducing morbidity and mortality of ...
Knuth, Alexander +15 more
core +2 more sources
Human Vaccines & Immunotherapeutics, 2017 Vaccine-enhanced disease has been a major obstacle in developing a safe vaccine against respiratory syncytial virus (RSV). This study demonstrates the immunogenicity, efficacy, and safety of virus-like particle (VLP) vaccines containing RSV F (F VLP), G (
Hye Suk Hwang +10 more
doaj +1 more source
Towards an improved platform for dengue and Zika virus virus-like particle production
, 2022 FAME analysis Using GC-QTOF with HP-88 (100m) column for the manuscript entitled Towards an improved platform for dengue and Zika virus virus-like particle productionTHIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE.
Panya, A (via Mendeley Data) +1 more
core +1 more source
Bioanalytics for Influenza Virus-Like Particle Characterization and Process Monitoring
Frontiers in Bioengineering and Biotechnology, 2022 Virus-like particles (VLPs) are excellent platforms for the development of influenza vaccine candidates. Nonetheless, their characterization is challenging due to VLPs’ unique biophysical and biochemical properties. To cope with such complexity, multiple
Sofia B. Carvalho +12 more
doaj +1 more source
Norwalk virus-like particles as vaccines [PDF]
Expert Review of Vaccines, 2010 Noroviruses (NoV) cause the great majority of epidemic nonbacterial gastroenteritis in humans. Expression of the capsid protein in recombinant systems, including insect and plant cells, yields assembly of virus-like particles (VLPs) that mimic the antigenic structure of authentic virions, and are relatively acid- and heat-stable.
Melissa, Herbst-Kralovetz +2 more
openaire +2 more sources
The 5th Virus-like Particle and Nano-Particle Vaccines (VLPNPV) conference.
, 2019 Virus-like Particles (VLPs) and Nano-Particles (NPs) are promising vaccine platforms that have led to the successful development of commercially available vaccines.
Engeroff, Paul +6 more
core +1 more source
The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles [PDF]
, 2008 Copyright @ 2008 American Society for Microbiology.The production of virus-like particles (VLPs) constitutes a relevant and safe model to study molecular determinants of virion egress.
Kien, F. +23 more
core +1 more source
Cryotomography of budding influenza a virus reveals filaments with diverse morphologies that mostly do not bear a genome at their distal end [PDF]
, 2013 Influenza viruses exhibit striking variations in particle morphology between strains. Clinical isolates of influenza A virus have been shown to produce long filamentous particles while laboratory-adapted strains are predominantly spherical.
Swetha Vijayakrishnan +29 more
core +1 more source